Prevalence and Contributing Factors of Isoniazid Monoresistance and Multidrug-Resistant Tuberculosis in Almaty, Kazakhstan - Takeaways - MDSpire

Prevalence and Contributing Factors of Isoniazid Monoresistance and Multidrug-Resistant Tuberculosis in Almaty, Kazakhstan

  • By

  • Juliana G. E. Bartels

  • Nurlan Takenov

  • Lyailya Chingissova

  • Anar Rakisheva

  • Ainur Eleusizova

  • Venera Bismilda

  • Lyazzat Yeraliyeva

  • Yanis Ben Amor

  • January 29, 2026

  • 0 min

Share

  • 1

    Drug-resistant tuberculosis (DR-TB) complicates treatment, requiring second-line drugs that are more difficult and expensive to administer.

  • 2

    Kazakhstan has a high burden of multidrug-resistant tuberculosis (MDR-TB), with stable rates over the past two decades and significant prevalence among new and previously treated cases.

  • 3

    Isoniazid-resistant tuberculosis (Hr-TB) has been historically overlooked, yet it is crucial for effective treatment and prevention of further drug resistance.

  • 4

    This study is the first to estimate rates of Hr-TB and MDR-TB in Almaty, Kazakhstan, aiming to inform public health policy and improve treatment strategies.

  • 5

    Sputum samples were collected and analyzed to determine drug resistance rates, highlighting the need for accurate diagnosis and surveillance of TB in high-burden regions.

Original Source(s)

Prevalence and Contributing Factors of Isoniazid Monoresistance and Multidrug-Resistant Tuberculosis in Almaty, Kazakhstan

  • by Juliana G. E. Bartels, Nurlan Takenov, Lyailya Chingissova, Anar Rakisheva, Ainur Eleusizova, Venera Bismilda, Lyazzat Yeraliyeva, Yanis Ben Amor

  • January 29, 2026

Related Content

Effective Management of Pre-Extensively Drug-Resistant Tuberculous Meningoencephalomyelitis in Pregnant Patients Using a Bedaquiline and Delamanid Treatment Approach: A Case Study

Antibiotics May Not Help Mild COVID

A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.

When Obesity Meets Infection Risk

Researchers analyze data from Finnish cohorts and the UK Biobank to examine how body mass index relates to severe infections and their global burden.